Growing Pains For US FDA Oversight Of Opioids: Starting Over On Assessment Of REMS
Whether CME for pain management has the intended impact on prescribing is likely focus of new ‘suite of studies’ intended to assess the opioid REMS program. The challenges for FDA include teasing out the impact of the risk management program amid all the other public health efforts on opioids.
You may also be interested in...
Division of Mitigation Assessment and Medication Error Surveillance will be established within the Office of Surveillance and Epidemiology, a change aimed at strengthening postmarketing oversight of opioids and other drugs; new Office of Safety and Clinical Evaluation will be created in Office of Generic Drugs, where Orange Book staff also will get their own division.
Two physicians experienced in agency affairs and operations, former commissioner David Kessler and former principal deputy commissioner Joshua Sharfstein, are reportedly finalists to head Biden’s FDA.
Proposal would allow stakeholders to see data on REMS goals like provider training and the US FDA’s conclusions about their effectiveness.